(NASDAQ: LUNG) Pulmonx's forecast annual revenue growth rate of 7.5% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.5%.
Pulmonx's revenue in 2025 is $91,664,000.On average, 8 Wall Street analysts forecast LUNG's revenue for 2025 to be $3,774,351,093, with the lowest LUNG revenue forecast at $3,597,566,305, and the highest LUNG revenue forecast at $3,936,781,913. On average, 8 Wall Street analysts forecast LUNG's revenue for 2026 to be $3,964,293,685, with the lowest LUNG revenue forecast at $3,662,241,655, and the highest LUNG revenue forecast at $4,267,830,608.
In 2027, LUNG is forecast to generate $4,820,953,334 in revenue, with the lowest revenue forecast at $4,042,209,332 and the highest revenue forecast at $6,547,141,707.